BBIO vs EXEL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 06, 2026

BBIO

36.3
AI Score
VS
EXEL Wins

EXEL

37.0
AI Score

Investment Advisor Scores

BBIO

36score
Recommendation
SELL

EXEL

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BBIO EXEL Winner
Revenue 1.90B 791.36M EXEL
Net Income 640.61M -372.97M EXEL
Net Margin 33.7% -47.1% EXEL
Operating Income 768.18M -224.67M EXEL
ROE 34.9% 22.4% EXEL
ROA 25.5% -17.3% EXEL
Total Assets 2.51B 2.16B EXEL
Cash 304.77M 1.53B BBIO
Current Ratio 3.21 2.09 EXEL
Free Cash Flow 828.73M -313.35M EXEL

Relative Price Performance (Last 90 Days)

BBIO 1M: +20.4% · 3M: -2.1% EXEL 1M: +14.5% · 3M: +36.3%

Current Technical Phase

BBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 64.7 · Price: $78.17

EXEL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62

RSI (14): 61.9 · Price: $69.84

Fundamentals Snapshot

Metric BBIO EXEL
Market Cap — —
Forward P/E -286.0 16.3
Trailing P/E — 21.2
Revenue (TTM) — —
Revenue Growth 1.9% 0.1%
Gross Margin 0.9% 1.0%
Operating Margin -0.4% 0.4%
EPS -3.07 3.34
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, EXEL is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.